Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBT (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of EBT data on record, last reported at -$16.9 million in Q3 2025.

  • For Q3 2025, EBT changed 0.36% year-over-year to -$16.9 million; the TTM value through Sep 2025 reached -$73.4 million, down 5.42%, while the annual FY2024 figure was -$74.3 million, 22.27% down from the prior year.
  • EBT reached -$16.9 million in Q3 2025 per NWBO's latest filing, down from -$16.6 million in the prior quarter.
  • Across five years, EBT topped out at -$13.2 million in Q2 2021 and bottomed at -$22.5 million in Q2 2022.
  • Average EBT over 5 years is -$17.4 million, with a median of -$16.9 million recorded in 2025.
  • Peak YoY movement for EBT: crashed 148.49% in 2021, then surged 33.96% in 2023.
  • A 5-year view of EBT shows it stood at -$13.2 million in 2021, then plummeted by 46.81% to -$19.4 million in 2022, then grew by 15.54% to -$16.4 million in 2023, then dropped by 28.09% to -$21.0 million in 2024, then increased by 19.28% to -$16.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$16.9 million in Q3 2025, -$16.6 million in Q2 2025, and -$18.9 million in Q1 2025.